Core Insights - Waters Corporation reported strong fourth-quarter 2024 results with non-GAAP earnings of 4.10pershare,exceedingtheZacksConsensusEstimateby1.993.62 [1][3] - Net sales reached 872.7million,surpassingtheZacksConsensusEstimateof857 million, marking a 6.5% increase on a reported basis and an 8% increase on a constant-currency basis compared to the previous year [2][3] Financial Performance - The company experienced double-digit growth in the Pharma segment, with instrument sales and recurring revenue showing high-single-digit gains in constant currency [3] - Non-GAAP selling and administrative expenses decreased by 2.6% year-over-year to 168.5million,representingacontractionof180basispointsasapercentageofnetsales[8]−Researchanddevelopmentspendingroseby8.946.3 million, with the adjusted operating margin increasing by 60 basis points to 35.5% [9] Sales Breakdown - Waters operates under two segments: Waters (87.6% of net sales) with sales of 764.3million,up6.6108.4 million, reflecting 5.7% growth [4] - Sales by product category included Instruments at 419.6million(48.1301.8 million (34.6% of net sales, up 8.2%), and Chemistry at 151.3million(17.3498.8 million in sales (57.2% of net sales), increasing by 7.6% year-over-year, while the Industrial market saw sales of 264million(30.3109.9 million (12.6% of net sales, up 15%) [6] - Geographic sales included Asia at 272.9million(31.3321 million (36.8% of net sales, up 5.7%), and Europe at 278.8million(31.9325.4 million, with cash from operations increasing to 240.1millionfrom204.6 million in the prior quarter [10] - For Q1 2025, Waters expects non-GAAP earnings of 2.17−2.25 per share, with organic sales growth anticipated at 4-7% on a constant-currency basis, while total sales growth is projected at 1-4% [11][12]